Topics

PubMed Journals Articles About "Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis" - Page: 2 RSS

19:32 EST 16th February 2020 | BioPortfolio

Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis articles that have been published worldwide.

More Information about "Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis" on BioPortfolio

We have published hundreds of Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis news stories on BioPortfolio along with dozens of Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis Clinical Trials and PubMed Articles about Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis Companies in our database. You can also find out about relevant Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis Drugs and Medications on this site too.

Showing "Ruxolitinib Siremadlin Crizanlizumab MBG453 Myelofibrosis" PubMed Articles 26–50 of 77

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Fedratinib (SAR302503, TG101348) is an orally administered Janus kinase (JAK) 2-selective inhibitor that is being developed for the treatment of patients with myelofibrosis (MF). The objectives of this analysis were to develop a population pharmacokinetic (PK) model to characterize fedratinib concentration-time profiles in patients with MF, polycythemia vera (PV) and essential thrombocythemia (ET) following oral fedratinib administration; and to investigate the effects of selected covariates on fedratinib P...


Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes.

To confirm that neoplastic monocyte-derived collagen- and fibronectin-producing fibrocytes induce bone marrow (BM) fibrosis in primary myelofibrosis (PMF), we injected PMF BM-derived fibrocyte-precursor CD14+/CD34- monocytes into the tail vein of NOD-SCID-γ (NSG) mice. PMF BM-derived CD14+/CD34- monocytes engrafted and induced a PMF-like phenotype with splenomegaly, myeloid hyperplasia with clusters of atypical megakaryocytes, persistence of the JAK2V617F mutation, and BM and spleen fibrosis. As control we...

Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF across three international centers and evaluated their significance. N/KRAS variants were present in 6% of patients and were typically sub-clonal (median VAF = 20%) relative to other genes vari...


Autoimmune panmyelosis with myelofibrosis.

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Colony-stimulating factor-3 receptor ()-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of mutation status.

Ruxolitinib as monotherapy in a patient with anaplastic lymphoma kinase positive lung adenocarcinoma.

We present unusual treatment outcome in a 59-year-old male diagnosed with metastatic lung adenocarcinoma with a very good response to ruxolitinib as monotherapy. In June 2017, this patient was diagnosed with myeloproliferative neoplasm - Janus-associated kinases 2 positive - and in December 2017 ruxolitinib therapy was started. At the same time, patient was diagnosed with lung adenocarcinoma in the left lower lobe with positive anaplastic lymphoma kinase mutation and with right lower lobe metastasis. Becaus...

Severe acquired platelet dysfunction because of primary myelofibrosis with full functional and morphological recovery after allogeneic hematopoietic cell transplantation.

: Primary myelofibrosis (PMF) is a clonal hematopoietic stem cell disorder characterized by fibrosis of the marrow cavity, marked megakaryocyte atypia and progressive cytopenias. Although thrombosis predominates, bleeding is the primary manifestation in up to 20% of patients and may be life-threatening. In this report, we document restoration of megakaryocyte and platelet structure and function in PMF after allogeneic hematopoietic cell transplantation (HCT). A 59-year-old man presented with recurrent episo...

TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis.

Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

Proactive steps to optimize the management of polycythemia vera and myelofibrosis.

Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation.

Graft versus host disease (GVHD) is a common complication of allogeneic stem cell transplantation (allo-SCT) with a high mortality. Although calcineurin inhibitors (CNI) have been widely used in the prophylaxis of GVHD, the incidence of acute GVHD (aGVHD) remains about 30%-50%. Moreover, some patients received allo-SCT could not tolerate CNI. Thus, improved GVHD prevention methods are still needed. Our study aimed to determine the prophylactic value of ruxolitinib for GVHD in the CNI-intolerant patients aft...

Driver Mutation-Specific Clinical and Genomic Correlates Differ Between Primary and Secondary Myelofibrosis.

Systemic Inflammation and Myelofibrosis in a Patient with Takenouchi-Kosaki Syndrome due to CDC42 Tyr64Cys Mutation.

Achievement of Durable and Complete Remission of Graft-versus-host Disease After Liver Transplantation With Ruxolitinib: A Case Report.

The Use of Ruxolitinib for Acute Graft-versus-Host Disease Developing After Solid Organ Transplantation.

Development of graft-versus-host disease (GvHD) is a rare complication after transfusions or solid organ transplantation. Patients typically present with a skin rash, diarrhea, liver failure, and bone marrow aplasia. A diagnosis of transfusion/transplantation associated-GvHD is made based on the clinical and histologic evidence, yet it is often delayed due to the nonspecific symptoms attributed to the patient's underlying illness. Several therapeutic approaches are being used including both increasing and w...

The role of JAK inhibitors in multiple myeloma.

Multiple myeloma (MM) is the most common primary malignancy of the bone marrow. No established curative treatment is currently available for patients diagnosed with MM. In recent years, new and more effective drugs have become available for the treatment of MM. Many newer drugs have been evaluated together and in combination with older agents. However, even in combination with other active MM agents, the responses are transient, and; thus, therapeutic approaches to help overcome resistance to these drugs ar...

Cellular cytokine receptor signaling and ATM pathway intersections affect hepatic DNA repair.

Pathways involving ataxia telangiectasia mutated (ATM) gene and its downstream partners and effectors are critical for the DNA damage response. Cell survival, proliferation and tissue homeostasis are dependent upon preservation of DNA integrity but additional intracellular mechanisms contribute in these processes. As receptor-mediated signaling with beneficial intersections in ATM pathways could have therapeutic significance, we interrogated such intersections with assays using HuH-7 cells (hepatocytes). Th...

Mutational profiling in myelofibrosis: implications for management.

Mutational profiling, usually by targeted next-generation sequencing, is increasingly performed on patients with myeloproliferative neoplasm-associated myelofibrosis (MF), whether primary (PMF) or post-polycythemia vera/essential thrombocythemia (post-PV/ET MF). "Driver" mutations in JAK2, MPL and indels in CALR underlie the vast majority of cases of PMF and post-ET MF; the remainder (≈ 10%) lack identifiable driver mutations, but other clonal markers are usually detectable. Nearly all patients with pos...

The role of fibrocytes in myelofibrosis and fibrocyte regulation as a novel treatment approach.

Recently, monocyte-derived fibroblast-like cells, called fibrocytes, garnered attention as involved in the novel pathogenesis of various fibrotic diseases. They also play a role in the induction of myelofibrosis (MF). Neoplastic fibrocytes are overrepresented in the bone marrow of patients with primary MF, and the suppression of fibrocyte differentiation by serum amyloid P has been shown to remarkably improve MF. Further, thrombopoietin (TPO) or a TPO receptor agonist directly induces fibrocyte differentiat...

Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy.

In adoptive T-cell immunotherapy of cancer, expansion and persistence of effector cells is a key determinant of response. We tested whether T lymphocytes could be rendered sensitive to erythropoietin (Epo) through ectopic expression of its wild-type receptor, or a truncated form (EpoRm) which augments Epo signaling in erythrocyte progenitors. Both receptors could be expressed in human T lymphocytes; Epo ligation induced STAT5 phosphorylation, which was abrogated by non-toxic concentrations of the JAK1/2 inh...

JAK-STAT-dependent regulation of scavenger receptors in LPS-activated murine macrophages.

In atherosclerosis progression, atherosclerotic plaques develop upon accumulated foam cells derived from macrophages that take up modified low-density lipoprotein (LDL). CD36 and CD204 are the principal scavenger receptors responsible for the uptake of modified LDL. Lipopolysaccharide (LPS) exacerbates atherosclerosis by enhancing the expression of scavenger receptors and thus increasing the uptake of modified LDL into macrophages. However, the signaling pathways that mediate LPS and scavenger receptor expr...

Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.

Chronic myeloproliferative neoplasms (MPN) are characterized by clonal expansion of an abnormal hematopoietic stem/progenitor cell and include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Venous thrombosis, often at unusual sites, including splanchnic vein thrombosis and arterial thrombosis, as well as a hemorrhagic tendency and a propensity to transform into myelofibrosis or acute leukemia are common complications in patients with MPNs. The pathogenesis of thromb...

Reduced Intensity Conditioning Allogeneic Transplant with Dual T-cell Depletion in Myelofibrosis.

There remains a significant mortality in recipients with MF who undergo allogeneic stem cell transplant (allo-HSCT). The combination of anti-thymoglobulin (ATG) and post-transplant cyclophosphamide (PTCy) provides good control of graft versus host disease (GVHD) when peripheral blood stem cell grafts are used.

Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity.

Primary Myelofibrosis (PMF) is a myeloproliferative disorder associated with JAK2V617F, Calreticulin (CALR) indels, and MPLW515L/K mutations activating the tyrosine kinase JAK2 and its downstream signaling pathway. The nature of signaling abnormalities in primary cells from PMF patients is poorly understood, since most of the work has been performed in cell lines or animal models. By flow cytometry we measured constitutive and cytokine induced phosphorylation of STAT5, STAT3, and ERK1/2 in circulating CD34+...

Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms.

BCR-ABL negative myeloproliferative neoplasms are acquired hematologic diseases characterized by blood cell proliferation and that include polycythemia vera (PV), essential thrombocytemia (ET) and primary myelofibrosis (PMF). Occurring of venous and arterial thrombosis is the main complication of these diseases. Risk factors for thrombosis are individuals older than 60 and history of thrombosis. The mechanisms leading to thrombosis are complex and involve several blood compartments, plasmatic factors and en...


Quick Search